secwatch.observer — SEC 8-K summary
======================================

Issuer:     COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK:        0001267565
Form:       8-K
Filed at:   2025-03-17T23:59:59+00:00
Accession:  0001104659-25-024185
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Collegium nominates Carlos Paya; founder Heffernan retires as Chairman, Santini named; appoints David Dieter as GC
--------------------------------------------------------------------------------

- Dr. Carlos Paya nominated for election to Board at 2025 Annual Meeting; current venture partner at Abingworth/Carlyle.
- Founder and Chairman Michael Heffernan will not stand for re-election and retire from Board at Annual Meeting.
- Gino Santini named Chairman of the Board effective immediately after Annual Meeting; Heffernan to serve as Chairman until then.
- Director Gwen Melincoff also retiring from Board at Annual Meeting; departures part of board refreshment, not due to disagreements.
- David Dieter appointed EVP and General Counsel effective March 17, 2025; previously VP Legal at Horizon Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267565/000110465925024185/0001104659-25-024185-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267565/000110465925024185/tm259415d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-024185

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer